Viracta Therapeutics (FRA:RYI) Preferred Dividends : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Viracta Therapeutics's preferred dividends for the three months ended in Mar. 2024 was €0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Viracta Therapeutics Preferred Dividends Historical Data

The historical data trend for Viracta Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Preferred Dividends Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Preferred Dividends

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Preferred Dividends	Get a 7-Day Free Trial												-	-	-	-	-

Viracta Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Viracta Therapeutics (FRA:RYI) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Viracta Therapeutics (FRA:RYI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.